Argenx stock gained 1.93 percent as pipeline access expands

Published on 10/07/2026 at 14:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock now has access to eight ENHANZE targets after Halozyme expanded the pact on October 6, 2026. Q2 revenue beat consensus by USD 90 million.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock was last at USD 930.52 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, up 1.93 percent from the prior close. The move followed an expansion of the company’s drug-delivery collaboration with Halozyme, giving argenx exclusive access to eight ENHANZE targets instead of six, according to PR Newswire on October 6, 2026.

Eight targets broaden ENHANZE access

The agreement supports development and commercialization of additional subcutaneous therapies in argenx’s immunology pipeline. Halozyme remains eligible for milestone payments and royalties on net sales of products using ENHANZE, while the two new targets were not disclosed, according to PR Newswire.

The arrangement builds on VYVGART Hytrulo, a subcutaneous treatment for myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy. For argenx, the commercial value lies in extending an established delivery platform across more pipeline programs rather than adding a disclosed near-term revenue figure.

Q2 revenue beat by USD 90 million

argenx reported Q2 2026 revenue of USD 1.54 billion, compared with the USD 1.45 billion analyst consensus, while quarterly earnings per share reached USD 7.32 against USD 5.86 expected, according to MarketBeat on October 4, 2026. Revenue therefore exceeded consensus by USD 90 million, while EPS exceeded the estimate by USD 1.46.

The company’s Q2 net income was USD 472.0 million, compared with USD 366.0 million in Q1 2026. Cash and cash equivalents stood at USD 3.584 billion at June 30, 2026, giving the pipeline expansion a substantial balance-sheet base.

Consensus target sits above Nasdaq price

MarketBeat reported a Moderate Buy consensus from 24 firms on October 4, 2026, comprising 17 buy ratings, two strong-buy ratings and five hold ratings. The average 12-month price target was USD 1,158.61, which lies 24.5 percent above the October 6 Nasdaq price of USD 930.52.

The market value was USD 57.9 billion on October 6, 2026, and trading volume reached 430,062 shares. The stock’s 52-week range was USD 661.85 to USD 1,072.75, placing the latest price USD 142.23 below the yearly high.

Argenx stock gained on October 6

Argenx stock was last at USD 930.52 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. The combination of a 1.93 percent daily gain, Q2 revenue above consensus and access to two additional ENHANZE targets keeps execution across the immunology pipeline central to the valuation.